CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT03448393 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

NIH

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, B Cell
B-Cell Lymphoma
B-Cell Leukemia
Acute Lymphoid Leukemia
B-Non Hodgkin Lymphoma
B-NHL
B-All
Acute Lymphoblastic Leukemia
Acute Lymphocytic Leukemia

Interventions

BIOLOGICAL: CD19/CD22 CAR T-Cells
DRUG: Fludarabine
DRUG: Cyclophosphamide
PROCEDURE: Apheresis
OTHER: Anti-emetic
DRUG: Diphenhydramine
DRUG: Acetaminophen
DIAGNOSTIC_TEST: ECG
DIAGNOSTIC_TEST: ECHO
DIAGNOSTIC_TEST: MRI Brain
PROCEDURE: Bone marrow biopsy
DIAGNOSTIC_TEST: Cardiac MRI

Sponsor

National Cancer Institute (NCI)